Pluri (PLUR) Long-Term Investments (2011 - 2025)
Pluri (PLUR) posted quarterly Long-Term Investments of $591000.0 for Q4 2025, up 12.14% year-over-year from $527000.0 in Q4 2024, and down 9.63% quarter-over-quarter from $654000.0 in Q3 2025.
Pluri (PLUR) Long-Term Investments (2011 - 2025) Analysis & Trends
Pluri (PLUR) has reported Long-Term Investments for 15 consecutive years, with $591000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Long-Term Investments rose 12.14% year-over-year to $591000.0; the TTM figure through Dec 2025 stood at $591000.0 (up 12.14% YoY), while the FY2025 annual figure was $610000.0, up 29.79% from the prior year.
- Long-Term Investments eased to $591000.0 in Q4 2025 per PLUR's latest filing, from $654000.0 in the prior quarter.
- Across five years, Long-Term Investments topped out at $18.5 million in Q3 2021 and bottomed at $426000.0 in Q3 2023.
- Historically, Long-Term Investments has averaged $1.6 million across 5 years, with a median of $567000.0 in 2022.
- Annual changes were most pronounced in 2021 — Long-Term Investments soared 2761.15% — and 2022, when it tumbled 96.69%.
- Pluri's Long-Term Investments stood at $717000.0 in 2021, then fell by 24.27% to $543000.0 in 2022, then retreated by 15.29% to $460000.0 in 2023, then increased by 14.57% to $527000.0 in 2024, then gained by 12.14% to $591000.0 in 2025.
- Business Quant data shows PLUR's Long-Term Investments at $591000.0 in Q4 2025, $654000.0 in Q3 2025, and $610000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.77 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.17 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 372.10 Mn |
| 10 | Pluri | 16.21 Mn | 3.72 Mn | 86,000.00 | 591,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 591,000.00 |
| Sep 30, 2025 | 654,000.00 |
| Jun 30, 2025 | 610,000.00 |
| Mar 31, 2025 | 514,000.00 |
| Dec 31, 2024 | 527,000.00 |
| Sep 30, 2024 | 493,000.00 |
| Jun 30, 2024 | 470,000.00 |
| Mar 31, 2024 | 459,000.00 |
| Dec 31, 2023 | 460,000.00 |
| Sep 30, 2023 | 426,000.00 |
| Jun 30, 2023 | 439,000.00 |
| Mar 31, 2023 | 437,000.00 |
| Dec 31, 2022 | 543,000.00 |
| Sep 30, 2022 | 611,000.00 |
| Jun 30, 2022 | 661,000.00 |
| Mar 31, 2022 | 4.24 Mn |
| Dec 31, 2021 | 717,000.00 |
| Sep 30, 2021 | 18.48 Mn |
| Jun 30, 2021 | 664,000.00 |
| Mar 31, 2021 | 695,000.00 |